Core Points - The company held its first extraordinary general meeting of shareholders for 2025 on September 25, 2025, with a total of 263 shareholders and proxies present, representing 278,825,552 shares, which is 21.2640% of the total voting shares [3][4] - The meeting was convened in accordance with relevant laws and regulations, and the voting process was conducted both on-site and online [4][20] - Several resolutions were passed, including the amendment of the business scope and the cancellation of the supervisory board, which received 98.9834% approval from the voting shareholders [5][6] Meeting Attendance and Voting - The meeting was attended by company directors, supervisors, senior management, and appointed lawyers, ensuring compliance with legal requirements [4][20] - The voting results showed that 275,990,952 shares were in favor of the resolution to amend the business scope, with only 936,800 shares against it [5][6] - Small shareholders accounted for 0.6795% of the total voting shares, with 68.1845% voting in favor of the resolution [5][8] Resolutions Passed - The following governance documents were amended and approved: - Shareholders' Meeting Rules: 98.4910% approval [7][9] - Board Meeting Rules: 98.4910% approval [10][11] - Independent Director Work System: 98.5457% approval [12][13] - External Guarantee Management System: 98.4953% approval [13][14] - Related Party Transaction Management System: 98.5244% approval [14][15] - External Investment Management System: 98.5166% approval [15][16] - Fundraising Management System: 98.5457% approval [17][18] - Accounting Firm Selection System: 98.5319% approval [18][19] - Director and Senior Management Compensation Management System: 98.5610% approval [19] Legal Verification - The meeting was witnessed by lawyers from Beijing Guofeng (Shenzhen) Law Firm, who confirmed that the meeting's procedures were in compliance with legal and regulatory requirements [20]

Meeting Details - The shareholder meeting was held on September 15, 2025, at 14:30, with online voting available throughout the day [3][4] - The meeting was attended by 176 shareholders, representing 210,863,381 shares, which is 16.4006% of the total shares [5] - The meeting was convened by the company's board of directors and presided over by Chairman Xu Renshuo [4][6] Proposal Review and Voting Results - The meeting approved the proposal to amend the company's articles of association with 208,392,581 votes in favor, accounting for 98.8282% of the votes cast [7][8] - The proposal to revise the company's shareholder meeting rules was also approved with the same voting results [10] - Other governance proposals, including amendments to the board meeting rules, independent director work system, external guarantee management system, related party transaction management system, and fundraising management system, were all passed with similar high approval rates, generally above 98% [10][11][12][13] Legal Opinion - The legal opinion provided by Guangdong Jingcheng Yueheng Law Firm confirmed that the meeting's procedures, qualifications of the convenor and attendees, and voting processes complied with legal and regulatory requirements [13]

Core Viewpoint - The document outlines the management and usage of raised funds by Jiangxi Fuxiang Pharmaceutical Co., Ltd., emphasizing the establishment of a clear investment management system to ensure the safety and efficiency of fund usage while protecting the rights of the company and its shareholders [1][2]. Fund Management System - The company must establish a system for the storage, usage, modification, supervision, and accountability of raised funds, including clear approval authority and risk control measures [1][2]. - The board of directors is responsible for ensuring the effective implementation of this system [2][4]. Fund Storage Management - Raised funds must be stored in a special account approved by the board of directors, and these accounts should not hold non-raised funds or be used for other purposes [2][3]. - A tripartite supervision agreement must be signed between the company, the sponsoring institution, and the commercial bank where the funds are stored [3][4]. Fund Usage Management - Funds must be used according to the investment plan outlined in the issuance application documents, and any significant deviations must be reported to the Shenzhen Stock Exchange [5][6]. - The company is prohibited from using raised funds for financial investments, such as trading financial assets or lending to others [6][7]. Fund Usage Change - Changes in the use of raised funds require board and shareholder approval, and the company must conduct feasibility analyses for new projects [18][19]. - If the remaining funds from completed projects are less than 5% of the net amount raised, the company may use them for other purposes without going through the usual approval process [14]. Supervision and Reporting - The board must conduct a comprehensive review of the progress of investment projects every six months and report on the storage and usage of raised funds [24][25]. - The sponsoring institution is required to conduct on-site inspections of the fund management every six months and issue a special verification report annually [25][26].